Endowment Funds Can Revolutionise Sarcoma Care in Developing Countries

Despite global childhood cancer mortality rates dropping by half over the past 50 years, these promising statistics do not extend to Africa and the Global South, where limited resources mean that most cancers are diagnosed at advanced stages. Consequently, the region reports survival rates of as low as 15% for musculoskeletal sarcomas, a group of cancers that develop in the bones and soft tissues of the body, when it has spread to other areas of the body from the original location. Endowment funds offer a sustainable way to radically enhance cancer care in under-resourced regions. These funds are an investment portfolio that draws its initial capital from donations and thereafter—when managed effectively—becomes interminable. The aim is to create a financial foundation that supports a wide array of initiatives, including research, treatment, training, and infrastructural development, making equitable, high-quality care a reality for all. Examples can be drawn from the Aga Khan University Faculty of Health Sciences Endowment and the more famous Harvard Endowment. A large corpus of capital is invested, and the returns generated from that investment are then used to fund initiatives the endowment supports perpetually. AKU endowment, valued at approximately USD 63 million (PKR 1,151,195,960), supports academic posts, student scholarships, research, and patient welfare, ensuring long-term financial security for the university.